

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
22 September 2005 (22.09.2005)

PCT

(10) International Publication Number  
**WO 2005/087806 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 14/705**

(21) International Application Number:  
PCT/US2005/004357

(22) International Filing Date: 9 February 2005 (09.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/544,369 13 February 2004 (13.02.2004) US

(71) Applicant (for all designated States except US):  
**BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.** [US/US]; 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LI, Jun** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 (US). **LI, Xiang** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 (US). **LOSACCO, Baerbel** [DE/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 (US). **QI, Zhenhao** [CN/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 (US).

(74) Agents: **MORRIS, Michael, P.** et al.; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CD38 SPLICE VARIANTS AND USES THEREOF

(57) Abstract: The invention provides for a substantially purified polypeptide referred to herein as CD38JL that is a CD38 splice variant comprised of the polypeptide of SEQ ID NO: 1 or a fragment thereof. The invention also provides methods for treating preventing and diagnosing disorders associated with expression of CD38JL.



WO 2005/087806 A2

**CD38 SPLICE VARIANTS AND USES THEREOF****5 RELATED APPLICATIONS**

This application claims benefit to U.S. provisional application No. 60/544,369 filed February 13, 2004 and the contents are incorporated herein.

**BACKGROUND OF THE INVENTION****10 1. TECHNICAL FIELD**

The present invention relates generally to the fields of molecular biology and inflammation. More specifically, the present invention relates to the identification of novel variants of CD38 and uses thereof.

**15 2. BACKGROUND INFORMATION**

T-lymphocytes bearing the CD4 receptor (CD4<sup>+</sup>), called CD4<sup>+</sup> T cells, augment the immune response by secreting cytokines that stimulate either a cytotoxic T cell response (T-helper 1) or an antibody response (T-helper 2). Naïve CD4<sup>+</sup> T cells can differentiate to Th1 or Th2 cells after the engagement of TCR-peptide-MHC class II complex, depending on the existing cytokines in the environment. Thus, CD4<sup>+</sup> T cells play critical roles in T cell-mediated immune responses. Novel genes that function in T cell activation may provide novel drug targets for autoimmune and inflammatory disease. Accordingly, the identification and characterization of novel genes which are involved in the activation of CD4<sup>+</sup> T cells is considered important.

25 CD38 is a multifunctional cell surface antigen that functions in cell adhesion, signal transduction and calcium signaling. CD38 catalyzes the production of cyclic ADP-ribose (cADPR) from its substrate NAD<sup>+</sup>. Takasawa, S. Et al.. (1993) *J. Biol. Chem.* 268: 26052-26054. cADPR acts as a second messenger that regulates intracellular calcium release. CD38 is expressed in hematopoietic cells including T lymphocytes, B lymphocytes and neutrophils. CD38 <sup>-/-</sup> mice shows a complete loss of tissue-associated NAD<sup>+</sup> glycohydrolase activity and exhibited marked deficiencies in antibody responses to T cell-dependent protein antigens. Cockayne, et al. (1998) *Blood* 92: 1324-1333. CD38 controls neutrophil chemotaxis to bacterial chemoattractants through its production of cyclic ADP-

ribose, and acts as a critical regulator of inflammation and innate immune responses.

Partida-Sanchez S, et al. (2002) *Nat Med* 7:1209-16. The human cDNA of CD38 was first cloned in 1990 and it encodes 300 amino acids. Jackson, D. G.; Bell, J. I. (1990) *J. Immun.* 144: 2811-2815 . It was reported that the CD38 gene is present in a single copy and  
5 extends over more than 62 kb. It consists of 8 exons and 7 introns, including a long intron that interrupts the 5-prime coding region. Ferrero, E.; Malavasi, F. (1997) *J. Immun.* 159: 3858-3865. The structure of the CD38 protein is unknown.

Cell surface antigens like CD38 have been known to occur in different isoforms that are  
10 structurally and functionally different from one another. For example CXCR-3 has two isoforms, CXCR3A and CXCR3-B, that have been found to have different biological activities and to trigger different signal transduction pathways. CXCR3-B shows high affinity only for CXCL4 where CXR3-A does not . Lasagni L *et al*, J Exp Med. 2003, 197:1537-49).

15 One cDNA splicing isoform of CD38, which only encodes 122 amino acid residues, was isolated from a human testis library. (Nata, K. *et al*, 1997, *Gene* 186, 285292).

The discovery of a new isoform for CD38 and the polynucleotides encoding it satisfies a  
20 need in the art by providing new compositions which may be used in the treatment, prevention and diagnosis of autoimmune and immunological diseases.

## **BRIEF SUMMARY OF THE INVENTION**

25 The invention provides for a substantially purified polypeptide referred to herein as CD38JL that is a CD38 splice variant comprised of 81 amino acid polypeptide of SEQ ID NO: 1 or a fragment thereof. |Amino Acid residues 1 through 57 of SEQ. ID. NO. 1 correspond to amino acid residues found in the CD38 sequence| and with which ADP-ribosylcyclase activity is associated. |

30 The invention also provides for a substantially purified polypeptide fragment of CD38JL comprised of residues residues 58-81 of the polypeptide sequence of SEQ ID NO: 1.

The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprised of the amino acid sequence of SEQ ID NO: 1 or a fragment of SEQ ID NO: 1 and in particular a fragment comprised of amino acid residues 58-81 of SEQ ID NO. 1.

The invention also provides for isolated and purified polynucleotides of 10 or more bases selected from SEQ ID NO: 2 and particularly bases 188-508 and 775-1884 of SEQ ID NO: 2.

The invention also provides an isolated and purified polynucleotide variant having at least 90% polynucleotide identity to the polynucleotide encoding the polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or a fragment thereof.

The invention further provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or a fragment of SEQ ID NO: 1, as well as an isolated and purified polynucleotide which is substantially complementary to the polynucleotide encoding the polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or a fragment of SEQ ID NO: 1.

The invention also provides for an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide consisting of the amino acid sequence of SEQ ID NO: 1. In another embodiment the expression vector is contained in a host cell.

Another embodiment of the invention provides for a method of treating IBD (Inflamed Bowel Disease) comprising the step of administering to a patient in need thereof a therapeutically effective of CD38JL splice variant polypeptide inhibitor or antagonist.

Another embodiment of the invention provides for a method of treating IBD (Inflamed Bowel Disease) comprising the step of administering to a patient in need thereof a therapeutically effective of CD38JL splice variant agonist.

The present invention also provides a pharmaceutical composition comprising a substantially purified polypeptide of SEQ ID NO: 1 in conjunction with a suitable pharmaceutical carrier.

5

The invention also provides a method for treating or preventing IBD, Psoriasis, rheumatoid arthritis or autoimmune diseases, said method comprised of the steps of administering to a patient in need thereof an therapeutically effective amount a CD38JL inhibitor and or an antagonist.

10

Another embodiment of the invention relates to a method of treating inflammatory disease in a human comprising the step of administrating to a patient in need of such treatment a therapeutically acceptable amount of a CD38JL inhibitor. Such a method of treatment is likely to be useful in the treatment of IBD, Psoriasis, rheumatoid arthritis and autoimmune diseases.

15

The invention also provides a method for detecting a polynucleotide sequence encoding CD38JL in a biological sample containing nucleic acids, said method comprised of the steps of:

20

a) hybridizing the complement of the polynucleotide encoding the polypeptide comprising the sequence of SEQ ID NO: 1 or a fragment of SEQ ID NO: 1 to at least one of the nucleic acids of the biological sample, thereby forming a hybridization complex; and

25

(b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide encoding CD38JL in the biological sample.

Other aspects, features and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention.

30

## **BRIEF DESCRIPTION OF THE FIGURES**

**FIG. 1** shows the sequence of the cDNA clone LJ-2 that encodes CD38JL.

**FIG. 2** shows the chromosomal mapping of the cDNA clone LJ-2.

5 **FIG. 3** shows an alignment of the polypeptide sequence of CD38JL and CD38.

**FIG. 4** shows the mRNA expression profile of AI989354 in normal human tissues.

10 **FIG. 5** shows mRNA expression of AI989354 in various inflamed tissues vs. normal tissues.

**FIG. 6** shows mRNA expression profile of AI989354 in stimulated and non-stimulated CD4+ T cells as measured by Affymatrix U95 genechip arrays.

15 **FIG. 7** shows the predicted longest open reading frame of the cDNA clone LJ-2 (starting from MET)

**FIG. 8** shows the alignment of the longest open reading frame of the CD 38 splice variant LJ-2.

20

## **DETAILED DESCRIPTION OF THE INVENTION**

It is understood that this invention is not limited to any particular, protocol, tools, and reagents as described, and that these may vary. It is also understood that the terminology  
25 used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.

Unless defined otherwise, all technical and scientific terms used herein are intended to have the same meanings as commonly understood by one of ordinary skill in the art in the  
30 field of the invention.

The use of the singular forms of the terms "a", "an," and "the" include plural reference unless the context clearly indicates otherwise.

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) (hereinafter "Maniatis"); and by Silhavy, T. J., Bannan, M. L. and Enquist, L. W., Experiments with Gene Fusions, Cold Spring Harbor Laboratory Cold Press Spring Harbor, N.Y. (1984); and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience (1987). "Nucleic Acid Hybridization" [B. D. Hames & S. J. Higgins eds. (1985)]; "Transcription and Translation" [B. D. Hames & S. J. Higgins eds. (1984)]; "Animal Cell Culture" [R. I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984). Therefore, if appearing herein, the following terms shall have the definitions set out below.

Nucleotide sequences are presented herein by single strand, in the 5' to 3' direction, from left to right, using the one letter nucleotide symbols as commonly used in the art and in accordance with the recommendations of the IUPAC-IUB Biochemical Nomenclature Commission (Biochemistry, 1972, 11 :1726-1732).

As used herein the term "CD38JL" refers to the amino acid sequences of substantially purified of the CD38 variant identified herein of any species and preferably mammalian species including man, from any source and either natural or synthetic.

As used herein the term "polypeptide" is used interchangeably with amino acid residue sequences or protein and refers to polymers of amino acids of any length. These terms also include proteins that are post-translationally modified through reactions that include, but are not limited to, glycosylation, acetylation, phosphorylation or protein processing. Modifications and changes, for example fusions to other proteins, amino acid sequence substitutions, deletions or insertions, can be made in the structure of a polypeptide while

the molecule maintains its biological functional activity. For example certain amino acid sequence substitutions can be made in a polypeptide or its underlying nucleic acid coding sequence and a protein can be obtained with like properties.

5 As used herein, the term "**cDNA**" in the context of this invention refers to deoxyribonucleic acids produced by reverse transcription and typically second-strand synthesis of mRNA or other RNA produced by a gene. If double-stranded, a cDNA molecule has both a coding or sense and a non-coding or antisense strand.

10 The terms "**fragment**" of the present invention refer herein to proteins or nucleic acid molecules which can be isolated/purified, synthesized chemically or produced through recombinant DNA technology. All these methods are well known in the art. As exemplified herein below, the nucleotide sequences and polypeptides used in the present invention can be modified, for example by in vitro mutagenesis.

15 As used herein the term "**agonist**" means a molecule which when bound to CD38JL increases or prolongs the duration of the effect of CD38JL. An agonist may include proteins, nucleic acids, carbohydrates and any other molecule that may bind to and regulate the effect of CD38JL.

20 As used herein the term "**antagonist**," refers to a molecule which, when bound to CD38JL, decreases the amount or the duration of the effect of the biological or immunological activity of CD38JL. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of CD38JL.

25 As used herein the term "**encoding**" refers to the inherent property of specific sequences of nucleotides in a nucleic acid, to serve as templates for synthesis of other molecules having a defined sequence of nucleotides (i.e. rRNA, tRNA, other RNA molecules) or amino acids and the biological properties resulting therefrom. Thus a gene encodes a protein, if  
30 transcription and translation of mRNA produced by that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and non-

coding strand, used as the template for the transcription, of a gene or cDNA can be referred to as encoding the protein or other product of that gene or cDNA. A nucleic acid that encodes a protein includes any nucleic acids that have different nucleotide sequences but encode the same amino acid sequence of the protein due to the degeneracy of the genetic code. Nucleic acids and nucleotide sequences that encode proteins may include introns.

The terms "**vectors**" or "**DNA construct**" are commonly known in the art and refer to any genetic element, including, but not limited to, plasmid DNA, phage DNA, viral DNA and the like which can incorporate the oligonucleotide sequences, or sequences of the present invention and serve as a DNA vehicle into which DNA of the present invention can be cloned. Numerous types of vectors exist and are well known in the art.

The terminology "**expression vector**" defines a vector or vehicle as described above but designed to enable the expression of an inserted sequence following transformation into a host. The cloned gene (inserted sequence) is usually placed under the operation of control element sequences such as promoter sequences. Such expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host or both (shuttle vectors) and can additionally contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements, and/or translational initiation and termination sites.

The term "**oligonucleotide**", as used herein refers to two or more molecules of deoxyribonucleotides adenine (A), guanine (G), thymine (T) and/or cytosine (C). The term "oligonucleotide" can be found in linear DNA molecules or fragments, viruses, plasmids, vectors, chromosomes or synthetically derived DNA. As used herein, DNA sequences are described according to the normal convention of giving only the sequence in the 5' to 3' direction.

As used herein the term "**polynucleotide**" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO: 2 or the complement thereof. The term "stringent hybridization conditions" is used as generally understood in the art. For example the term

can mean an overnight incubation at 42°C in a solution comprising 50% formamide, 5 X. SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5X. Denhardt's solution, 10% dextran sulfate, and 20 .mg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at about 60°C. The exact conditions  
5 required for "high stringency" may vary depending on the nature of the nucleic acid samples (i.e. DNA:DNA or DNA:RNA).

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency  
10 of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 ° C. in a solution comprising 6X SSPE (20X SSPE=3M NaCl; 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide,  
15 100 mu.g/ml salmon sperm blocking DNA; followed by washes at 50 ° C. with 1X SSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

The conditions may be varied by adding or removing various blocking reagents. Blocking  
20 reagents can include Denhardt's reagent, heparin, BLOTTO, denatured salmon sperm DNA, and commercially available product. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

25 The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can  
30 be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

Two DNA sequences are "**substantially complementary**" when at least about 75% (preferably at least about 80%, and most preferably at least about 90% or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., supra; DNA Cloning, Vols. I & II, supra; Nucleic Acid Hybridization, supra.

- As used herein, the term "**host**" is meant to include not only prokaryotes but also eukaryotes such as yeast, plant and animal cells. A recombinant DNA molecule or gene which encodes a protein of the present invention can be used to transform a host using any of the techniques commonly known to those of ordinary skill in the art. Prokaryotic hosts may include *E. coli*, *S. typhimurium*, *Serratia marcescens* and *Bacillus subtilis*. Eukaryotic hosts include yeasts such as *Pichia pastoris*, mammalian cells and insect cells.

- The terms "**amino acid**" or "**amino acid sequence**," as used herein, refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments", "immunogenic fragments", or "antigenic fragments" refer to arrangements of CD38JL splice variant which are preferably about 5 to about 15 amino acids in length. Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

- The term "**antigenic determinant**," as used herein, refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The terms "**complementary**" or "**complementarity**," as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base pairing.

- 5 The term "**homology** or **identity**," as used herein, refers to a degree of complementarity. There may be partial homology or complete homology. A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a
- 10 hybridization assay under conditions of reduced stringency.

- The phrases "**percent identity**" or "**% identity**" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program
- 15 (Lasergene software package, DNASTAR, Inc., Madison Wis.). The MEGALIGN program can create alignments between two or more sequences according to different methods, e.g., the clustal method. (Higgins, D. G. and P. M. Sharp (1988) Gene 73:237-244). Percent identity between nucleic acid sequences can also be calculated by the clustal method, or by other methods known in the art, such as the Jotun Hein method. (See, e.g.,
- 20 Hein, J. (1990) Methods in Enzymology 183:626-645.) Identity between sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

- "**Hybridization**," as the term is used herein, refers to any process by which a strand of
- 25 nucleic acid binds with a complementary strand through base pairing.

- As used herein, the term "**hybridization complex**" as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g.,
- 30 C<sub>0</sub> t or R<sub>0</sub> t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes,

filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

5 The term "**microarray**," as used herein, refers to an array of distinct polynucleotides or oligonucleotides arrayed on a substrate, such as paper, nylon or any other type of membrane, filter, chip, glass slide, or any other suitable solid support.

10 The term "**substantially purified**," as used herein, refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% separated from other cellular or viral components. Thus, for example, a "purified protein" has been purified to a level not found in nature.

15 A "**variant**" of CD38JL, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include  
20 amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

25

## THE INVENTION

Using techniques including expression profile analysis, an EST AI989354 which is highly induced in activated CD4<sup>+</sup> T cells was identified. This EST sequence is located between known exons III and IV of the human CD38 gene. Using the EST AI989354 as bait, a 1.9  
30 kb cDNA clone (LJ-2) was isolated from a human peripheral lymphocyte cDNA library. The polynucleotide sequence for clone LJ-2 is shown in FIG. 1 and SEQ. ID. NO: 2. The cDNA sequence for LJ-2 was mapped on the CD38 gene locus on human chromosome 4

and found to share Exons I and II with CD38 (as shown in FIG. 2) and thus encodes a novel CD38 splice variant. FIG. 3 shows the alignment of polypeptides of CD38 and the CD38JL splice variant. The first 57 amino acids of CD38JL correspond to that of a portion of the CD38 sequence and the remaining amino acid residues (58-81) of CD38JL do not directly correspond to the CD38 sequence.

FIG. 4 shows the distribution of A1989354 expression in normal tissues. Data were obtained from affymetrix U95 genechip experiments according to the method as described in the Affymetrix Gene Chip® Expression Analysis Technical Manual. There is elevated expression of A1989354 in various tissues including the thymus.

FIG. 5 shows the distribution of A1989354 expression in various inflamed tissues vs. normal tissues also obtained with Affymatrix analysis. CD38JL is also induced in tissues derived from patients with IBD and both Ulcerative Colitis and Chron's disease D. Enhanced expression in tissues of this origin suggests that the splice variant may play a role in T cell activation and may therefore provide a novel drug target for autoimmune and inflammatory disease. FIG. 6 shows the expression of A1989354 in CD4 T cells as measured by Affymatrix U95 genechip arrays.

FIG. 7 and SEQ ID. NO: 1 show the 81 amino acid polypeptide predicted translate of the CD38 JL-2 cDNA. FIG. 8 shows the sequences of the CD38 translate starting with the first MET alongside the cDNA sequence of CD38JL cDNA. The exon positions including boundary are labeled, sequences different from CD38 are underlined.

One embodiment of the invention comprises an isolated polypeptide of amino acid sequence of SEQ ID NO: 1. CD38JL is 81 Amino acids long. As shown in FIG. 7 and FIG. 8 CD38JL bears homology to CD38 and has a potential ADP-ribosyl cyclase domain. The invention also encompasses derivatives of the CD38JL splice variant. A preferred derivative will have at least 90% polynucleotide identity to the polynucleotide encoding the polypeptide consisting of amino acid sequence of SEQ ID NO: 1. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of CD38JL.

It will be appreciated by those skilled in the art that a multitude of polynucleotide sequences encoding CD38JL, some bearing minimal homology to the polynucleotide sequences of any known and naturally occurring gene may be produced due to the degeneracy of the genetic code. Thus, the present invention also contemplates variations of polynucleotide sequence that could be made by selecting combinations based on alternative codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring CD38JL.

Although nucleotide sequences which encode CD38JL and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring CD38 under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding CD38JL or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding CD38JL without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode CD38JL and CD38JL derivatives, or fragments thereof, entirely by chemical synthesis chemists.

Synthetic sequences may be inserted into expression vectors and host cell systems using reagents that are well known in the art. Moreover synthetic chemistry may be used to introduce mutations into a sequence encoding CD38JL or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO: 2, or a fragment of SEQ ID NO: 2, under various conditions of stringency.

(See, e.g., Wahl, G. M. and S. L. Berger (1987) *Methods Enzymol.* 152:399-407; and Kimmel, A. R. (1987) *Methods Enzymol.* 152:507-511.)

5 CD38JL-encoding nucleotide sequences possessing non-naturally occurring codons may be used. For example, codons preferred by a prokaryotic host can be used to increase protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

10 The nucleotide sequences of the present invention can be altered using methods generally known in the art in order to alter CD38JL-encoding sequences such as by cloning, processing, and/or expression of the gene product. Recombinant DNA techniques and synthetic oligonucleotides may be used to alter the nucleotide sequences.

15 In another embodiment of the invention, the polynucleotides encoding CD38JL, or derivative thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding CD38JL may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding CD38JL. Thus, complementary molecules or fragments may be used to modulate CD38JL activity. Such  
20 technology is now well known in the art, and sense or antisense, or siRNA, RNA interference oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding CD38JL. RNA interference oligos and anti-sense oligos could be designed using the sequence of CD38 splice variant to specifically inhibit the function of the CD38 isoform. RNA interference is a process  
25 employing sequence-specific post-transcriptional gene silencing or gene knockdown by providing a double-stranded RNA (dsRNA) that is homologous in sequence to the targeted gene. Small interfering RNAs (siRNAs) can be synthesized in vitro or generated by ribonuclease III cleavage from longer dsRNA and are the mediators of sequence-specific mRNA degradation. SiRNA can be designed according to the technique described by  
30 Tuschl, described as follows. Elbashir, SM et al, *Nature*, 2001, 411, 494-498. Suitable siRNA for the instant invention can be double stranded ribonucleic acid comprising a first

strand of nucleotides that is substantially identical to 19 to 25 consecutive nucleotides of SEQ ID NO. 2, and a second strand that is substantially complementary to the first.

The protein encoded by this novel CD38 variant could be selected for use in protein therapeutics. For example, monoclonal antibodies against CD38 splice variant polypeptides can be produced. Methods for producing monoclonal antibodies against isolated proteins and their administration to cells are known in the art. *Am J Gastroenterol.* 2002, 97:2962-72. Monoclonal antibodies directed against the CD38 splice variant polypeptides of the invention can be administered to cells to inhibit the function of the protein, and therefore to treat autoimmune or inflammatory diseases.

It is also contemplated that the CD38 splice variant of the present invention can be used in screening assays and ultra high throughput assays to identify small molecule inhibitors of the CD38 splice variant polypeptides. Small molecule inhibitors could block the binding of this CD38 variant to its cell surface receptor. It is known that CD38 is involved in adhesion and rolling of lymphocytes on endothelial cells through the interaction with CD31. [Dianzani, U., Stockinger, H., and Malavasi, F. (1998) *J Immunol* 160, 395-402]. Therefore, blocking by small inhibitors in vivo could affect lymphocyte adhesion.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding CD38JL may be ligated to a heterologous sequence to encode a fusion protein. For example, peptide libraries can be screened for inhibitors of CD38JL activity. It may also be useful to encode a chimeric CD38JL protein that can be recognized by antibodies that are commercially available. Fusion proteins may also be made to contain cleavage sites between the CD38JL encoding sequence and other heterologous protein sequence, so that CD38JL may be cleaved and purified away from the heterologous moiety.

### Polypeptides

Polypeptide sequences encoding CD38JL or a fragment thereof may be synthesized, by employing chemical methods well known in the art. (See, e.g., Caruthers, M. H. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, and Horn, T. et al. (1980) *Nucl. Acids Res.*

Symp. Ser. 225-232.) Synthesized peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g, Chiez. R. M, and F. Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic formed peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g.,  
5 Creighton, T. (1983) *Proteins, Structures and Molecular Properties*, W H Freeman and Co., New York, N.Y.)

Additionally, the amino acid sequence of CD38JL, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part  
10 thereof, to produce a variant polypeptide. It is also contemplated that CD38JL may be produced not only by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, T. E. (1984) *Protein: Structures and Molecular Properties*, pp. 55-60, W. H. Freeman and Co., New York, N.Y.). Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using  
15 the Applied Biosystems 431A peptide synthesizer (Perkin Elmer). Fragments of CD38JL may be synthesized separately and then combined to produce the full length molecule.

CD38JL or its derivatives may be made by inserting cDNA sequences encoding into an expression vector with appropriate regulatory elements necessary for the transcription and  
20 translation of the inserted coding sequence according to methods known in the art. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview, N.Y., ch. 4, 8, and 16-17; and Ausubel, F. M. et al. (1995, and periodic supplements) *Current Protocols in Molecular*  
25 *Biology*, John Wiley & Sons, New York, N.Y., ch. 9, 13, and 16.)

Fragments of CD38JL may be produced by recombinant production using techniques well known in the art. Host cells transformed with nucleotide sequences encoding CD38JL will be cultured under conditions suitable for the expression an isolation of CD38JL protein  
30 from cell culture. It is also understood that expression vectors containing nucleic acid sequences encoding CD38JL may be engineered to contain signal sequences that direct secretion of CD38JL through a the cell membrane or otherwise facilitate purification of

the protein. Such purification domains include metal chelating peptides that allow for purification on immobilized metal, protein A domains that allow purification on immobilized immunoglobulin.

- 5 It is contemplated that polynucleotide probes derived from CD38JL polynucleotide sequences may be useful as probes or diagnostics for autoimmune and inflammatory conditions. Accordingly, the invention provides isolated and purified polynucleotides comprised of 10 or more bases selected from SEQ ID No: 1 and from bases 188-508 and 775-1884 of SEQ ID NO. 1.

10

Polynucleotide sequences encoding CD38JL may be used for the diagnosis of a disorder associated with expression of CD38JL splice variant. Examples of such diseases include IBD, and other inflammatory diseases such as IBD, Psoriasis, rheumatoid arthritis, and autoimmune diseases.

15

In another embodiment of the invention a vector capable of expressing CD38JL or a derivative thereof may be administered to a subject to treat or prevent an immunological disease.

20

In another embodiment, an agonist which modulates the activity of CD38JL may be administered to a subject to treat or prevent an immunological disease.

In another embodiment of the invention an antagonist which modulates the activity of CD38JL may be administered to a subject to treat or prevent an immunological disease.

25

CD38JL antagonists may be produced using methods known in the art. An antagonist is believed to be more effective for the advantageous modulation of the CD38JL associated enzyme function. Either the agonist or the antagonist could work based on its function.

30

Purified CD38JL may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind CD38JL. CD38JL antibodies may also be generated using methods understood in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain

antibodies, Fab fragments, and fragments produced by a Fab expression library.

Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

5 Various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with CD38JL or with any fragment or oligopeptide thereof which has immunogenic properties and or antigenic determinants. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and  
10 surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol.

Preferably oligopeptides, peptides, or fragments used to induce antibodies to CD38JL should have an amino acid sequence consisting of at least about 5 amino acids, and, more  
15 preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Chimeric molecules comprised of short stretches of CD38JL and other proteins are also contemplated.

20 CD38JL monoclonal antibodies may be prepared using known methods for producing of antibody molecules by continuous cell lines in culture. These include, but are not limited to, hybridoma techniques, the human B-cell hybridoma techniques, and the EBV-hybridoma techniques. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R. J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; and Cole, S. P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)  
25

CD38JL antibodies may also be produced by inducing in vivo production in the lymphocyte cells or by screening immunoglobulin libraries or of highly specific binding  
30 reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci.* 86: 3833-3837; and Winter, G. et al. (1991) *Nature* 349:293-299.)

CD38JL specific antibodies may be identified using various immunoassays known in the art. Such immunoassays typically involve the measurement of antigen-antibody complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering CD38JL epitopes is preferred, but a competitive binding  
5 assay may also be employed. Antibodies to CD38JL may be useful as therapeutics in the treatment of inflammatory conditions. Thus in one embodiment of the invention provides A purified antibody that binds specifically to a poly.peptide of SEQ ID. No. 1

### **Diagnostics**

10 In another embodiment, antibodies which specifically bind CD38JL may be used for the diagnosis of disorders characterized by expression of CD38 or CD38JL, or in assays to monitor patients being treated with CD38JL polypeptides agonists, antagonists, or inhibitors of CD38JL. Antibodies useful for diagnostic purposes may be prepared using methods described herein. Diagnostic assays for CD38JL include methods which utilize  
15 the antibody and a label to detect CD38JL in samples (tissue, cell, fluids) from in human body. The antibodies are then optionally modified and or labeled by covalent or non-covalent attachment of a reporter molecule.

A variety of protocols for detecting the presence of proteins such as CD38JL are known in  
20 the art including ELISAs, RIAs, and FACS. These methods can be used diagnose abnormal levels of CD38JL expression. Normal or standard values for CD38JL expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to CD38JL under conditions suitable for complex formation. The amount of standard complex formation may be  
25 measured by various methods, preferably by photometric means. The levels of CD38JL that are expressed in subject, tissue samples are then compared with the standard values. The deviation between standard and subject values are calculated and used to establish the parameters for diagnosing disease.

30 The polynucleotides encoding CD38JL may be used for diagnostic purposes. The types of polynucleotides which may be used include oligonucleotide sequences, RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene

expression in tissues samples in which expression of CD38JL may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of CD38JL, and to monitor regulation of CD38JL levels during therapeutic intervention.

5

In one embodiment of the invention PCR probes directed to CD38JL specific sequence may be used to identify nucleic acid sequences which encode CD38JL. The specificity of the probe, whether it is made from a highly specific region, e.g., and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding CD38JL, alleles, or related sequences.

10

Nucleic acid probes may also be used for the detection of related sequences, and preferably contain at least about 60% of the nucleotides from any of the CD38JL encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO: 2.

15

Polynucleotide sequences encoding CD38JL may be used for the diagnosis of a disorder associated with expression of CD38JL.

20

#### **Methods for detecting and measuring expression of CD38JL**

Methods for detecting and measuring expression of proteins such as CD38JL with polyclonal or monoclonal antibodies specific for the protein, are understood in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul, Minn., Section IV; and Maddox, D. E. et al. (1983) J. Exp. Med. 158:1211-1216). Preferred techniques include used include enzyme-linked immunosorbent assays (ELISAs), fluorescence activated cell sorting (FACS) and radioimmunoassays (RIAs). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on CD38JL can be used as well as a competitive binding assay.

25

30

There are a number of labels and conjugation techniques that can be used in various nucleic acid and amino acid assays and these are known in the art. Means for producing

labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding CD38JL include but are not limited to end-labeling, and PCR amplification using a labeled nucleotide. Alternatively, mRNA probes containing the sequences encoding CD38JL and derivatives thereof can be engineered using techniques known in the art. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase. Reporter molecules or labels which may be used to detect molecules of interest include but are not limited to radionuclides, chromogenic agents, fluorescent, chemiluminescents.

#### 10 **General Administration and Pharmaceutical Compositions**

The invention also provides methods of modulating CD38JL function in a patient comprising administering to the patient a compound according to the invention. If the purpose of modulating the CD38JL function in a patient is to treat a disease-state or condition, the administration preferably comprises a therapeutically or pharmaceutically effective amount of a pharmaceutically acceptable compound according to the invention. If the purpose of modulating the CD38JL function in a patient is for a diagnostic or other purpose (e.g., to determine the patient's suitability for therapy or sensitivity to various sub-therapeutic doses of the compounds according to the invention), the administration preferably comprises an effective amount of a compound according to the invention, that is, the amount necessary to obtain the desired effect or degree of modulation.

The compounds of the invention can be typically administered in the form of a pharmaceutical composition. Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the invention. The compounds of the invention may also be administered alone or in combination with adjuvants that enhance stability of the compounds of the invention, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increased inhibitory activity, provide adjunct therapy, and the like. The compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances. In general, the compounds of

this invention are administered in a therapeutically or pharmaceutically effective amount, but may be administered in lower amounts for diagnostic or other purposes.

Administration of the compounds of the invention, in pure form or in an appropriate pharmaceutical composition, can be carried out using any of the accepted modes of administration of pharmaceutical compositions. Thus, administration can be, for example, orally, buccally (e.g., sublingually), nasally, parenterally, topically, transdermally, vaginally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages. The pharmaceutical compositions will generally include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, vehicles, or combinations thereof. Such pharmaceutically acceptable excipients, carriers, or additives as well as methods of making pharmaceutical compositions for various modes or administration are well-known to those of skill in the art. The state of the art is evidenced, e.g., by Remington: The Science and Practice of Pharmacy, 20th Edition, A. Gennaro (ed.), Lippincott Williams & Wilkins, 2000; Handbook of Pharmaceutical Additives, Michael & Irene Ash (eds.), Gower, 1995; Handbook of Pharmaceutical Excipients, A.H. Kibbe (ed.), American Pharmaceutical Ass'n, 2000; H.C. Ansel and N.G. Popovich, Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th ed., Lea and Febiger, 1990; each of which is incorporated herein by reference in their entireties to better describe the state of the art.

As one of skill in the art would expect, the forms of the compounds of the invention utilized in a particular pharmaceutical formulation will be selected (e.g., salts) that possess suitable physical characteristics (e.g., water solubility) that is required for the formulation to be efficacious.

Pharmaceutical compositions suitable for buccal (sub-lingual) administration include lozenges comprising a compound of the present invention in a flavored base, usually

sucrose, and acacia or tragacanth, and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Pharmaceutical compositions suitable for parenteral administration can comprise sterile aqueous preparations of a compound of the present invention. These preparations are preferably administered intravenously, although administration can also be effected by means of subcutaneous, intramuscular, or intradermal injection. Injectable pharmaceutical formulations are commonly based upon injectable sterile saline, phosphate-buffered saline, oleaginous suspensions, or other injectable carriers known in the art and are generally rendered sterile and isotonic with the blood. The injectable pharmaceutical formulations may therefore be provided as a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, including 1,3-butanediol, water, Ringer's solution, isotonic sodium chloride solution, fixed oils such as synthetic mono- or diglycerides, fatty acids such as oleic acid, and the like. Such injectable pharmaceutical formulations are formulated according to the known art using suitable dispersing or setting agents and suspending agents. Injectable compositions will generally contain from 0.1 to 5% w/w of a compound of the invention.

Solid dosage forms for oral administration of the compounds can include capsules, tablets, pills, powders, and granules. For such oral administration, a pharmaceutically acceptable composition containing a compound(s) of the invention is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, pregelatinized starch, magnesium stearate, sodium saccharine, talcum, cellulose ether derivatives, glucose, gelatin, sucrose, citrate, propyl gallate, and the like. Such solid pharmaceutical formulations may include formulations, as are well-known in the art, to provide prolonged or sustained delivery of the drug to the gastrointestinal tract by any number of mechanisms, which include, but are not limited to, pH sensitive release from the dosage form based on the changing pH of the small intestine, slow erosion of a tablet or capsule, retention in the stomach based on the physical properties of the formulation, bioadhesion of the dosage form to the mucosal lining of the intestinal tract, or enzymatic release of the active drug from the dosage form.

Liquid dosage forms for oral administration of the compounds can include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs, optionally containing pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like. These compositions can also contain additional  
5 adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.

Topical dosage forms of the compounds include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, eye ointments, eye or ear drops, impregnated  
10 dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams. Topical application may be once or more than once per day depending upon the usual medical considerations. Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles. The  
15 formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation, more usually they will form up to about 80% of the formulation.

20 Transdermal administration is also possible. Pharmaceutical compositions suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Such  
25 patches suitably contain a compound of the invention in an optionally buffered, aqueous solution, dissolved and/or dispersed in an adhesive, or dispersed in a polymer. A suitable concentration of the active compound is about 1% to 35%, preferably about 3% to 15%.

For administration by inhalation, the compounds of the invention are conveniently  
30 delivered in the form of an aerosol spray from a pump spray device not requiring a propellant gas or from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,

dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide, or other suitable gas. In any case, the aerosol spray dosage unit may be determined by providing a valve to deliver a metered amount so that the resulting metered dose inhaler (MDI) is used to administer the compounds of the invention in a reproducible and controlled way. Such inhaler, nebulizer, or atomizer devices are known in the prior art, for example, in PCT International Publication Nos. WO 97/12687 (particularly Figure 6 thereof, which is the basis for the commercial RESPIMAT® nebulizer); WO 94/07607; WO 97/12683; and WO 97/20590, to which reference is hereby made and each of which is incorporated herein by reference in their entireties.

Rectal administration can be effected utilizing unit dose suppositories in which the compound is admixed with low-melting water-soluble or insoluble solids such as fats, cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights, or fatty acid esters of polyethylene glycols, or the like. The active compound is usually a minor component, often from about 0.05 to 10% by weight, with the remainder being the base component.

In all of the above pharmaceutical compositions, the compounds of the invention can be formulated with an acceptable carrier or excipient. The carriers or excipients used must, of course, be acceptable in the sense of being compatible with the other ingredients of the composition and must not be deleterious to the patient. The carrier or excipient can be a solid or a liquid, or both, and is preferably formulated with the compound of the invention as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compound. Such carriers or excipients include inert fillers or diluents, binders, lubricants, disintegrating agents, solution retardants, resorption accelerators, absorption agents, and coloring agents. Suitable binders include starch, gelatin, natural sugars such as glucose or  $\beta$ -lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

Generally, a therapeutically effective daily dose would be from about 0.001 mg to about 15 mg/kg of body weight per day of a compound of the invention; preferably, from about 0.1 mg to about 10 mg/kg of body weight per day; and most preferably, from about 0.1 mg to about 1.5 mg/kg of body weight per day. For example, for administration to a 70 kg person, the dosage range would be from about 0.07 mg to about 1050 mg per day of a compound of the invention, preferably from about 7.0 mg to about 700 mg per day, and most preferably from about 7.0 mg to about 105 mg per day. Some degree of routine dose optimization may be required to determine an optimal dosing level and pattern.

Pharmaceutically acceptable carriers and excipients encompass all the foregoing additives and the like.

## EXAMPLES OF THE INVENTION

### Example 1: Microarray analysis of CD4+ cells

Human CD4+ T cells were purified from peripheral blood obtained from donors and stimulated by anti-CD3 antibody + anti-CD28 antibody, or anti-CD3 antibody+ ICAM for 24 hours or 72 hours. The unstimulated cells are used as controls. Total RNA from these cells were extracted and quantified by analysis using Affymetrix U95 gene chips. We performed expression profile analysis and identified that EST(AI989354) is expressed highly induced during T cell activations (either by anti-CD3+anti-CD28 or by anti-CD3+ICAM) (FIG 6). The data were confirmed by T cell samples from three different donors. (Fig. 1)

### Example 2: Microarray analysis of normal tissues

The expression profile of the gene AI989354 in normal tissues were also obtained by Affymetrix U95 genechip experiments. RNA samples from multiple donors were used for each group of normal tissues. AI989354 is highly expressed in normal thymocytes (FIG. 4), suggesting that it is important function in T cells and immune systems. The expression of AI989354 in all other tested normal tissues was relatively low (FIG. 4). The selective expression in Thymus suggests that this gene has important immune functions and that this gene might make a good target because its modulation by inhibitors, antagonist or agonists

would have less side effects due to its low expression in other tissues.

### **Example 3: Isolation and sequencing of LJ-2**

The plasmid clone LJ-2 was isolated from the human peripheral blood leukocyte (PBL)  
 5 cDNA library array panels in the “Longest-Clone” cDNA library screening (Origene Technologies Inc, Rockville, MD). The human cDNA fragments were inserted into a vector, pCMV6-XL4, which size is 4.7 kb to construct the cDNA library. Approximately 6 million size-selected clones, derived from twelve human tissue library panels consisting of fetal and adult brain, heart, kidney, liver, lung, muscle, peripheral blood leukocytes,  
 10 placenta, small intestine, spleen, and testis, were arrayed into the 96-well “super plate”. Each well of the super plate contains 40,000 clones. For the library screen, three PCR primers were designed from AI989354 sequences

15	SEQ. ID. NO: 3: P1R (reverse primer)	GAGGTGTTGAGTCTTTCTGGGCA
	SEQ. ID. NO: 4: P2F (forward primer),	ATAGCCTGCTTCCGAATTCTTGG
	SEQ. ID. NO: 5: P3F (forward primer),	CCCATGCTCCCTAATTCCTTC
	SEQ. ID. NO: 6: VP3F (forward primer vector)	GACAGAGCTCGTTTAGTGAACC
	SEQ. ID. NO: 7: VP6R (reverse primer vector)	TAGAAGGACACCTAGTCAGAC

20 The super plate was screened by PCR using the pair of P3F/P1R primers. The positive wells were then rescreened using a pair of VP3F/P1R primers to identify the well with the longest clone. This well corresponds to a “master plate”, which contains 5,000 clones per well. The master plate was also screened using the VP3F/P1R primers to identify the well with the longest clone. The appropriate 96-well sub-plate, derived from the selected well  
 25 of the master plate and containing 50 clones per well, was screened by PCR using the P3F/P1R primers. Cells from the positive sub-plate well were then plated out and 96 individual colonies were picked and screened by PCR to identify the final clone using primer pairs of P3F/P1R, VP3F/P1R, P2F/VP6R, and P3F/VP6R. PCR products were amplified from one clone, LJ-2, by P3F/P1R (~436 bp), VP3F/P1R (~1.7 kb), P2F/VP6R  
 30 (~590 bp), and P3F/VP6R (~620 bp), respectively. The LJ-2 sequence which contains AI989354 sequence was obtained by sequencing the insert of clone LJ-2.

**Example 4: Microarray analysis of AI989354 expression in various inflamed tissues vs. normal tissues**

The mRNA expression of the gene AI989354 in a number of inflamed and normal control tissues were also obtained by Affymetrix U95 genechip experiments. AI989354 expression is induced in inflamed colon tissues from inflamed bowel disease patients (comparing colon tissues from 6 Crohn's Disease patients and 7 Ulcerative Colitis patients versus 39 normal colons) (FIG. 5). The gene is also induced in inflamed rectum and inflamed spleen as compared to the normal controls (FIG. 5). The induced expression of AI989354 in these inflamed tissues suggests that AI989354 may mediate inflammatory responses in these tissues.

**Example 5: Sequence search against database.**

A search of the SEQ ID NO: 1 against the InterPro database using the INTERPRO program was performed in order to obtain protein families, domains or sites that have a high degree of similarity to SEQ. ID NO: 1 This search revealed two protein families the PFO2267 family and the SSF56629 family. The PFO2267 family encodes a polypeptide having an ADP-ribosyl cyclase CD38/157. The e-value for PFO2667 5.9e-05. The SSF56629 family also has a ADP-ribosyl cyclase region. For SSF56629 the E-value was: 9e-23.

In the claims:

1. A substantially purified polypeptide comprised of the polypeptide of SEQ ID NO: 1 or a fragment thereof.  
5
2. The polypeptide of claim 1 comprised of amino acid residues 58-81 of SEQ ID NO: 1.
3. An isolated and purified polynucleotide encoding the polypeptide comprised of the amino acid sequence of SEQ ID NO: 1 or a fragment of SEQ ID NO: 1 comprised of  
10 amino acids 58-81.
4. An isolated and purified polynucleotide comprised of 10 or more bases selected from SEQ ID NO: 2.
- 15 5. An isolated and purified polynucleotide according to claim 4 wherein said polynucleotide is further comprised of 10 or more bases selected from bases 188-508 or 775-1884 of SEQ ID NO: 2.
6. An isolated and purified polynucleotide of 10 or more variant having at least 90%  
20 polynucleotide identity to the polynucleotide encoding the polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or a fragment thereof.
7. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide consisting of the amino acid sequence of SEQ  
25 ID NO: 1 or a fragment of SEQ ID NO: 1, as well as an isolated and purified polynucleotide which is substantially complementary to the polynucleotide encoding the polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or a fragment of SEQ ID NO: 1.
- 30 8. An expression vector containing at least a fragment of the polynucleotide encoding the polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

9. The expression vector of claim 8 contained in a host cell.
10. A method of treating inflamed bowel disease comprising the step of administering a patient in need thereof a therapeutically effective amount of CD38JL splice variant polypeptide agonist or antagonist to a patient in need thereof or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising a substantially purified polypeptide of SEQ ID NO: 1 of claim 1 in conjunction with a suitable pharmaceutical carrier.
12. A method of treating inflammatory disease in a human comprising the step of administering to a patient in need of such treatment a therapeutically effective amount of a CD38JL inhibitor.
13. A method for treating or preventing inflamed bowel disease, psoriasis, rheumatoid arthritis or autoimmune diseases, said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of CD38JL inhibitor and or an antagonist.
14. A method for detecting a polynucleotide sequence encoding CD38JL in a biological sample containing nucleic acids, said method comprised of the steps of:
- a) hybridizing the complement of the polynucleotide encoding the polypeptide comprising the sequence of SEQ ID NO: 1 or a fragment of SEQ ID NO: 1 to at least one of the nucleic acids of the biological sample, thereby forming a hybridization complex; and
  - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide encoding CD38JL in the biological sample.
15. A purified antibody that binds specifically to a polypeptide of SEQ ID. NO. 1.
16. A purified antibody that binds specifically to polypeptides 58-81 of SEQ ID. NO. 1.

17. A double stranded ribonucleic acid comprising a first strand of nucleotides that is  
5 substantially identical to 19 to 25 consecutive nucleotides of SEQ ID NO. 2, and a second  
strand that is substantially complementary to the first.


18. An antisense oligonucleotide that inhibits the endogenous expression of CD38 in a  
human cell.

10

**cDNA Sequence for Clone LJ-2**

	1	GAATTGCGCAC	CAGAAGAGCC	CAACTCTGTC	TTGGCGTCAG	TATCCTGGTC
5	51	CTGATCCTCG	TCGTGGTGCT	CGCGGTGGTC	GTCCCGAGGT	GGCGCCAGCA
	101	GTGGAGCGGT	CCGGGCACCA	CCAAGCGCTT	TCCCGAGACC	GTCTTGCGCGC
	151	GATGCGTCAA	GTACACTGAA	ATTCATCCTG	AGATGAGAAA	CAGCTAAAAG
	201	AAGTGAGTTG	GGCCAGGCAC	TGTGGCTCAC	ACCTGTAATC	CCAGCACTTT
	251	GGGAGGCCCA	GGCAGGTGGA	TCACTTAAGG	TCAGGAGTAC	AAGACCTGCC
10	301	TGGCCAACAT	GCTGAAACTC	CGTCTCTACT	AAAAATACAA	AATTAGCCGG
	351	GTGTTGTGGC	GCGTGCCTGT	AATCCCAGCT	ACTCTGGAGA	CTGAGGTGGG
	401	AGAATCGCTT	GAACCCAGGA	GGAGGAGGTA	GCACTGAACC	AAGATCCAGC
	451	CTGGCCAAGA	GAGTAAGACT	CCGTCTCAAA	ACCAAACCAA	ACCAAACCAA
	501	AAAAAGAAAC	ATGTAGACTG	CCAAAGTGTA	TGGGATGCTT	TCAAGGGTGC
15	551	ATTTATTTCA	AAACATCCTT	GCAACATTAC	TGAAGAAGAC	TATCAGCCAC
	601	TAATGAAGTT	GGGAACTCAG	ACCGTACCTT	GCAACAAGAT	TCTTCTTTGG
	651	AGCAGAATAA	AAGATCTGGC	CCATCAGTTC	ACACAGGTCC	AGCGGGACAT
	701	GTTACCCCTG	GAGGACACGC	TGCTAGGCTA	CCTTGCTGAT	GACCTCACAT
	751	GGTGTGGTGA	ATTCAACACT	TCCAGTGAGG	CTCTGGGCCC	TGTGGGATTG
20	801	CCCAGGGATG	TGGAGGGTGA	ACAGAGTGAC	TTCTGCTGGA	GGCCCTGAAT
	851	GATTAGTGTG	GAGGACAGAG	CCACAGGCAC	CCATCCTGAT	GCCATCTATA
	901	CTTATATTAG	TCCATTTGTG	TTGCTATTAA	GGAATACCTG	AGGCTGCGTA
	951	ATTTATAAAG	AAAAGAGGTT	TATTTGACTC	ACAGTTACGC	AGGCTGTACA
	1001	AGAAGTAGGG	TACCAGCATC	CACTTCGGGT	GAAAGCCTGA	GGCTGTTTCC
25	1051	ACTCATGGAG	AAGGGGAAGG	GGAGCTGGCA	TTTACAGAGA	TCACATGGTG
	1101	AGGGAGGAAA	GCAAGGAGAG	GTCAGGGGAG	GTGCCAGGCT	GTTTGTAATG
	1151	ACCAGCTGTC	CTGGGAACTA	GTAGAGTAAG	AACTCATTAC	TATAAGGACA
	1201	GCACCATGCC	ATTCGTGCAG	GATCATCCCT	ATGACCCAAA	CACCTCCTAC
	1251	TAGTCCCGAG	CTCCAACACT	GGGGGTGCGA	TTTCAACATA	AGGTTTGGAG
30	1301	AGTTAAATAT	CCAAACTATA	GCACTACCCT	TAATGGCAAC	TCAGGCTGAT
	1351	ATAAAGTAGC	ATTCCCTGTT	TTCTTGAAAA	ATTGACTTCA	GAGTTGGGGA
	1401	TTGCCCATGC	TCCCTAATTC	CCTTCTTTTG	AGTGCTCACA	TAGCCTGCTT
	1451	CCGAATTCTT	GGTATTTTGC	TCTCTGTAAG	GTCATCATTC	AGGTCCAAAG
	1501	AAGTCTAGAA	CAGGATGAGG	TCTCAGTGGG	ACCTAGACCA	AGGTTCTTGC
35	1551	TCTTCAGAA	CATCACAGTA	GCCATGGACT	GGACTCTTCC	ATCTCAGGCA
	1601	CTGGCTTTGC	CATCATTTTT	CAGATGTAGC	CTTACCCTGC	CCAGAAAGAC
	1651	TCAACACCTC	ACCAGGGGAA	GGGATTTCCT	ACAACCAAAA	CCCTACTGCA
	1701	GTTTTTCACTT	CTTTTTTTTTT	TCTTTTTTGT	TATATGGTGG	ATATTTTTTAC
	1751	TTTATATAGT	TTTATTCTTA	TTTTTACTGT	TTTTCATTGT	TTGTTTTTTAA
40	1801	AAGCTTATCT	TATTATAGCT	TCTTTGTCCC	AGGTTTGCAT	TACTTTCAAT
	1851	TACAAAAATA	AAGCATGATT	ATTTGAAAAA	AAAAAAAAAA	AAAACTCGAC


**FIG. 1**



**FIG. 2**

		1	50
	CD38_human	(1)	MANCEFSPVSGDKPCCRLSRRACLGLVLSILVLILVVVLAVVVPRWRQTW
	CD38JL_human	(1)	-----
	Consensus	(1)	-----
5		51	100
	CD38_human	(51)	SGPGTTKRFPETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCN
	CD38JL_human	(1)	-----
	Consensus	(51)	-----
		101	150
10	CD38_human	(101)	ITEEDYQPLMKLGTQTVPCNKILLWSRIKDLAQFTQVQORDMFTLEDTL
	CD38JL_human	(1)	-----MKLGTQTVPCNKILLWSRIKDLAQFTQVQORDMFTLEDTL
	Consensus	(101)	MKLGTQTVPCNKILLWSRIKDLAQFTQVQORDMFTLEDTL
		151	200
	CD38_human	(151)	GYLADDLTWCGEFNTSKINYQSCPDWRKDCSNNPVSVFWKTVSRRFAEAA
15	CD38JL_human	(42)	GYLADDLTWCGEFNTSSEALGPVGLPRDVEGEQ-SDFCWRP-----
	Consensus	(151)	GYLADDLTWCGEFNTS R N WK
		201	250
	CD38_human	(201)	CDVVHVMLNGSRSKIFDKNSTFGSVEVHNLQPEKVQTLQAWVIHGGREDS
	CD38JL_human	(82)	-----
20	Consensus	(201)	-----
		251	300
	CD38_human	(251)	RDLCQDPTIKELESIIISKRNIFQFSCKNIYRPDKFLQCVKNPEDSSCTSEI
	CD38JL_human	(82)	-----
	Consensus	(251)	-----
25			
30			

FIG. 3



5

**FIG. 4** Expression of AI989354 mRNA in normal human tissues was measured by Affymetrix U95 genechip arrays. Median expression values are presented here. The number of donor samples was indicated.




FIG. 5

5 FIG. 5 mRNA expression of AI989354 in various inflamed tissues vs. normal tissues. Median expression values were presented here. Data were obtained from Affymetrix U95 genechip experiments. The number of donor samples was indicated.

Expression of AI989354 in human CD4 T cell was measured by Affymetrix U95 genechip arrays. Primary CD4 T cells were isolated from three donors and stimulated with antiCD3+antiCD28 or antiCD3+ICAM for 24 hr or 72 hr.




FIG. 6

1 MKLGTQTVPC NKILLWSRIK DLAHQFTQVQ RDMFTLEDTL LGYLADDLTW  
51 CGEFNTSSEA LGPVGLPRDV EGEQSDFCWR P

5

**FIG. 7**

```

5      1      <-----
      1      GAATTCGCAC CAGAAGAGCC CAACTCTGTC TTGGCGTCAG TATCCTGGTC CTGATCCTCG
      CTTAAGCGTG GTCTTCTCGG GTTGAGACAG AACCGCAGTC ATAGGACCAG GACTAGGAGC
      -----exonI-----
      61      TCGTGGTGCT CGCGGTGGTC GTCCCGAGGT GGCGCCAGCA GTGGAGCGGT CCGGGCACCA
      AGCACCACGA GCGCCACCAG CAGGGCTCCA CCGCGGTCGT CACCTCGCCA GGCCCGTGGT
      -----
10     121      CCAAGCGCTT TCCCGAGACC GTCTTGGCGC GATGCGTCAA GTACACTGAA ATTCATCCTG
      GGTTTCGCGAA AGGGCTCTGG CAGGACCGCG CTACGCAGTT CATGTGAC'TT TAAGTAGGAC
      -----><=====
      181      AGATGAGAAA CAGCTAAAAG AAGTGAGTTG GGCCAGGCAC TGTGGCTCAC ACCTGTAATC
      TCTACTCTTT GTCGATTTTC TTCACTCAAC CCGGTCCGTG ACACCGAGTG TGGACATTAG
      -----
15     241      CCAGCACTTT GGGAGGCCCA GGCAGGTGGA TCAC'TTAAGG TCAGGAGTAC AAGACCTGCC
      GGTTCGTGAAA CCCTCCGGGT CCGTCCACCT AGTGAATTCC AGTCCTCATG TTCTGGACGG
      -----
20     301      TGGCCAACAT GCTGAAACTC CGTCTCTACT AAAAATACAA AATTAGCCGG GTGTTGTGGC
      ACCGGTTGTA CGACTTTGAG GCAGAGATGA TTTTATATGTT TTAATCGGCC CACAACACCG
      -----
      361      GCGTGCCTGT AATCCCAGCT ACTCTGGAGA CTGAGGTGGG AGAATCGCTT GAACCCAGGA
      CGCACGGACA TTAGGGTCGA TGAGACCTCT GACTCCACCC TCTTAGCGAA CTGGGGTCTT
      -----
25     421      GGAGGAGGTA GCACTGAACC AAGATCCAGC CTGGCCAAGA GAGTAAGACT CCGTCTCAAA
      CCTCCTCCAT CGTGACTTGG TTCTAGGTCG GACCGGTTCT CTCATTCTGA GGCAGAGTTT
      =====exonII=====><-----exonIII-----
      481      ACCAAACCAA ACCAAACCAA AAAAAGAAAC ATGTAGACTG CCAAAGTGTA TGGGATGCTT
      TGGTTTGGTT TGGTTTGGTT TTTTCTTTG TACATCTGAC GGTTTCACAT ACCCTACGAA
      -----
30     541      TCAAGGGTGC ATTTATTTCA AAACATCCTT GCAACATTAC TGAAGAAGAC TATCAGCCAC
      AGTTCACACG TAAATAAAGT TTTGTAGGAA CGTTGTAATG ACTTCTTCTG ATAGTCGGTG
      -----><-----
35     601      M K L G T Q T V P C N K I L L W S R I K
      TAATGAAGTT GGGAACTCAG ACCGTACCTT GCAACAAGAT TCTTCTTTGG AGCAGAATAA
      ATTACTIONCAA CCCTTGAGTC TGGCATGGAA CGTTGTTCTA AGAAGAAACC TCGTCTTATT
      -----exonIV-----
40     661      D L A H Q F T Q V Q R D M F T L E D T L
      AAGATCTGGC CCATCAGTTC ACACAGGTCC AGCGGGACAT GTTCACCCTG GAGGACACGC
      TTCTAGACCG GGTAGTCAAG TGTGTCCAGG TCGCCCTGTA CAAGTGGGAC CTCTGTGCG
      -----<=====
45     721      L G Y L A D D L T W C G E F N T S S E A
      TGCTAGGCTA CCTTGCTGAT GACCTCACAT GGTGTGGTGA ATTCAACACT TCCAGTGAGG
      ACATCCGAT GGAACGACTA CTGGAGTGTA CCACACCACT TAAGTTGTGA AGGTCACTCC
      -----
50     781      L G P V G L P R D V E G E Q S D F C W R
      CTCTGGGCCC TGTGGGATTG CCCAGGGATG TGGAGGGTGA ACAGAGTGAC TTCTGCTGGA
      GAGACCCGGG ACACCTTAAC GGGTCCCTAC ACCTCCCACT TGTCTCACTG AAGACGACCT
      =====
55     841      P
      GGCCCTGAAT GATTAGTGTG GAGGACAGAG CCACAGGCAC CCATCCTGAT GCCATCTATA
      CCGGGACTTA CTAATCACAC CTCCTGTCTC GGTGTCCGTG GGTAGGACTA CGGTAGATAT
      -----
      901      CTTATATTAG TCCATTTGTG TTGCTATTAA GGAATACCTG AGGCTGCGTA ATTTATAAAG
      GAATATAATC AGGTAAACAC AACGATAAAT CTTATGGAC TCCGACGCAT TAAATATTTT
      -----
      961      AAAAGAGGTT TATTTGACTC ACAGTTACGC AGGCTGTACA AGAAGTAGGG TACCAGCATC
      TTTTCTCCAA ATAAACTGAG TGTCAATGCG TCCGACATGT TCTTCATCCC ATGGTCGTAG
      -----
60     1021     CACTTCGGGT GAAGGCCTGA GGCTGTTTCC ACTCATGGAG AAGGGGAAGG GGAGCTGGCA
      GTGAAGCCCA CTTCCGGACT CCGACAAAGG TGAGTACCTC TTCCCCTTCC CCTCGACCGT
      -----
      1081     TTTACAGAGA TCACATGGTG AGGGAGGAAA GCAAGGAGAG GTCAGGGGAG GTGCCAGGCT
      AAATGTCTCT AGTGTACCAC TCCCTCCTTT CGTTCCTCTC CAGTCCCCTC CACGGTCCGA
      -----
65

```

Fig. 8-1

```

1141  GTTTGTAATG ACCAGCTGTC CTGGGAAC TA GTAGAGTAAG AACTCATTAC TATAAGGACA
      CAAACATTAC TGGTCGACAG GACCCTTGAT CATCTCATT C TTGAGTAATG ATATTCCTGT
      =====
5    1201  GCACCATGCC ATTCGTGCAG GATCATCCCT ATGACCCAAA CACCTCCTAC TAGTCCCGAG
      CGTGGTACGG TAAGCACGTC CTAGTAGGGA TACTGGGTTT GTGGAGGATG ATCAGGGCTC
      =====
      1261  CTCCAACACT GGGGGTCGAA TTTCAACATA AGGTTTGGAG AGTTAAATAT CCAAATA
      GAGGTTGTGA CCCCAGCTT AAAGTTGTAT TCCAAACCTC TCAATTATA GGTTCATAT
      =====
10   1321  GCACTACCTT TAATGGCAAC TCAGGCTGAT ATAAAGTAGC ATTCCCTGTT TTCTTGAAAA
      CGTGATGGGA ATTACCGTTG AGTCCGACTA TATTTCATCG TAAGGGACAA AAGAACCTTT
      =====
      1381  ATTGACTTCA GAGTTGGGGA TTGCCCATGC TCCCTAATTC CCTTCTTTTG AGTGCTCACA
      TAACTGAAAT CTCAACCCCT AACGGGTACG AGGGATTAAG GGAAGAAAAC TCACGAGTGT
      =====
15   1441  TAGCCTGCTT CCGAATTCTT GGTATTTTGC TCTCTGTAAG GTCATCATTC AGGTCCAAAG
      ATCGGACGAA GGCTTAAGAA CCATAAAACG AGAGACATTC CAGTAGTAAG TCCAGGTTTC
      -----
      =====
20   1501  AAGTCTAGAA CAGGATGAGG TCTCAGTGGG ACCTAGACCA AGGTTCTTGC TCTTCAGAAT
      TTCAGATCTT GTCCTACTCC AGAGTCACCC TGGATCTGGT TCCAAGAACG AGAAGTCTTA
      =====
      1561  CATCACAGTA GCCATGGACT GGACTCTTCC ATCTCAGGCA CTGGCTTTGC CATCATTTTT
      GTAGTGTCAT CGGTACCTGA CCTGAGAAGG TAGAGTCCGT GACCGAAACG GTAGTAAAAA
      =====
25   1621  CAGATGTAGC CTTACCCTGC CCAGAAAGAC TCAACACCTC ACCAGGGGAA GGGATTTCCT
      GTCTACATCG GAATGGGACG GGTCTTTCTG AGTTGTGGAG TGGTCCCCTT CCCTAAAGGA
      =====
      1681  ACAACCAAAA CCCTACTGCA GTTTTCACTT CTTTTTTTTT TCTTTTTTGT TATATGGTGG
30   TGTGTTGTTT GGGATGACGT CAAAAGTGAA GAAAAAAAAA AGAAAAACAA ATATACCACC
      =====
      1741  ATATTTTTTAC TTTATATAGT TTTATCTTAA TTTTACTGT TTTTCATTGT TTGTTTTTAA
      TATAAAAATG AAATATATCA AAATAAGAAT AAAAATGACA AAAAGTAACA AACAAAAATT
      =====
35   1801  AAGCTTATCT TATTATAGCT TCTTTGTCCC AGGTTTGCAT TACTTTCAAT TACAAAAATA
      TTCGAATAGA ATAATATCGA AGAAACAGGG TCCAAACGTA ATGAAAGTTA ATGTTTTTAT
      =====>
      1861  AAGCATGATT ATTTGAAAAA AAAAAAAAAA AAAACTCGAC
40   TTCGTACTAA TAACTTTTTT TTTTTTTTTT TTTTGAGCTG

```

FIG. 8-2

45 The longest Open reading frame of CD38JL (starting with 1<sup>st</sup> MET) is translated in the sequence panel of CD38 splice variant cDNA above (exon positions including boundary are labeled, sequences different from CD38 are under “=” sign).

50

55

SEQ ID NO: 1

```
1      MKLGTQTVPC NKILLWSRIK DLAHQFTQVQ RDMFTLEDTL GYLADDLTW
5  51    CGEFNTSSEA LGPVGLPRDV EGEQSDFCWR P
```

SEQ ID NO: 2

```

5      1      GAATTCGCAC CAGAAGAGCC CAACTCTGTC TTGGCGTCAG TATCCTGGTC
      CTTAAGCGTG GTCTTCTCGG GTTGAGACAG AACCGCAGTC ATAGGACCAG
      51      CTGATCCTCG TCGTGGTGCT CGCGGTGGTC GTCCCGAGGT GCGCGCCAGCA
      GACTAGGAGC AGCACCACGA GCGCCACCAG CAGGGCTCCA CCGCGGTTCGT
      101     GTGGAGCGGT CCGGGCACCA CCAAGCGCTT TCCCGAGACC GTCTTGCGCG
      10      CACCTCGCCA GGCCCGTGGT GGTTGCGGAA AGGGCTCTGG CAGGACCGCG
      151     GATGCGTCAA GTACACTGAA ATTCATCCTG AGATGAGAAA CAGCTAAAAG
      CTACGCACTT CATGTGACTT TAAGTAGGAC TCTACTCTTT GTCGATTTTC
      201     AAGTGAGTTG GGCCAGGCAC TGTGGCTCAC ACCTGTAATC CAGCACTTTT
      TTTACTCAAC CCGGTCCGTG ACACCGAGTG TGGACATTAG GTCGTGAAA
      15      251     GGGAGGCCCA GGCAGGTGGA TCACTTAAGG TCAGGAGTAC AAGACCTGCC
      CCTCCGGGT CCGTCCACCT AGTGAATTCC AGTCTCATG TCTTGACGG
      301     TGGCCAACAT GCTGAAACTC CGTCTCTACT AAAAATACAA AATTAGCCGG
      ACCGGTTGTA CGACTTTGAG GCAGAGATGA TTTTATGTT TTAATCGGCC
      20      351     GTGTTGTGGC GCGTGCCTGT AATCCCAGCT ACTCTGGAGA CTGAGGTGGG
      CACAACACCG CGCACGGACA TTAGGGTCGA TGAGACCTCT GACTCCACCC
      401     AGAATCGCTT GAACCCAGGA GGAGGAGGTA GCACTGAACC AAGATCCAGC
      TCTTAGCGAA CTTGGGTCTT CCTCCTCCAT CGTGACTTGG TCTAGGTCG
      451     CTGGCCAAGA GAGTAAGACT CCGTCTCAA ACCAAACCAA ACCAAACCAA
      GACCGTTCTT CTCATTCTGA GGCAGAGTTT TGGTTTGGTT TGGTTTGGTT
      25      501     AAAAAGAAAC ATGTAGACTG CCAAAGTGTA TGGGATGCTT TCAAGGGTGC
      TTTTCTTTTG TACATCTGAC GGTTCACAT ACCCTACGAA AGTTCCACG
      551     ATTTATTTCA AAACATCCTT GCAACATTAC TGAAGAAGAC TATCAGCCAC
      TAAATAAAGT TTTGTAGGAA CGTTGTAATG ACTTCTTCTG ATAGTCGGTG
      601     TAATGAAGTT GGGAACCTCAG ACCGTACCTT GCAACAAGAT TCTTCTTTGG
      30      ATTACTTCAA CCCTTGAGTC TGGCATGGAA CGTTGTTCTA AGAAGAAACC
      651     AGCAGAATAA AAGATCTGGC CCATCAGTTC ACACAGGTCC ACGGGGACAT
      TCGTCTTATT TTCTAGACCG GGTAGTCAAG TGTGTCCAGG TCGCCCTGTA
      701     GTTCACCCCTG GAGGACACGC TGCTAGGCTA CCTTGCTGAT GACCTCACAT
      CAAGTGGGAC CTCCTGTGCG ACGATCCGAT GGAACGACTA CTGGAGTGTA
      35      751     GGTGTGGTGA ATTCAACACT TCCAGTGAGG CTCTGGGCCC TGTGGGATTG
      CCACACCACT TAAGTTGTGA AGGTCACCTC GAGACCCGGG ACCCCTAAC
      801     CCCAGGGATG TGGAGGGTGA ACAGAGTGAC TTCTGCTGGA GCGCCTGAAT
      GGGTCCCCTAC ACCTCCCACT TGTCTCACTG AAGACGACCT CCGGGACTTA
      851     GATTAGTGTG GAGGACAGAG CCACAGGCAC CCATCCTGAT GCCATCTATA
      40      CTAATCACAC CTCCTGTCTC GGTGTCCGTG GGTAGGACTA CGGTAGATAT
      901     CTTATATTAG TCCATTTGTG TTGCTATTAA GGAATACCTG AGGCTGCGTA
      GAATATAATC AGGTAAACAC AACGATAATT CCTTATGGAC TCCGACGCAT
      951     ATTTATAAAG AAAAGAGGTT TATTTGACTC ACAGTTACGC AGGCTGTACA
      TAAATATTTT TTTTCTCCAA ATAAACTGAG TGTCAATGCG TCCGACATGT
      45      1001    AGAAGTAGGG TACCAGCATC CACTTCGGGT GAAGGCCTGA GCTGTTTCC
      TCTTCATCCC ATGGTCGTAG GTGAAGCCCA CTTCCGGACT CCGACAAAGG
      1051    ACTCATGGAG AAGGGGAAGG GGAGCTGGCA TTTACAGAGA TCACATGGTG
      TGAGTACCTC TTCCCCTTCC CCTCGACCGT AAATGTCTCT AGTGTAACCAC
      1101    AGGGAGGAAA GCAAGGAGAG GTCAGGGGAG GTGCCAGGCT GTTTGTAATG
      50      TCCCTCCTTT CGTTCCTCTC CAGTCCCCTC CACGGTCCGA CAAACATTAC
      1151    ACCAGCTGTC CTGGGAACTA GTAGAGTAAG AACTCATTAC TATAAGGACA
      TGGTCGACAG GACCCTTGAT CATCTCATTC TTGAGTAATG ATATTCCTGT
      1201    GCACCATGCC ATTCGTGCAG GATCATCCCT ATGACCCAAA CACCTCCTAC

55      CGTGGTACGG TAAGCACGTC CTAGTAGGGA TACTGGGTTT GTGGAGGATG

```

	1251	TAGTCCCGAG	CTCCAACACT	GGGGGTGAA	TTTCAACATA	AGGTTTGGAG
		ATCAGGGCTC	GAGGTTGTGA	CCCCAGCTT	AAAGTTGTAT	TCCAAACCTC
	1301	AGTTAAATAT	CCAAACTATA	GCACTACCTT	TAATGGCAAC	TCAGGCTGAT
		TCAATTTATA	GGTTTGATAT	CGTGATGGGA	ATTACCGTTG	AGTCCGACTA
5	1351	ATAAAGTAGC	ATTCCCTGTT	TTCTTGAAAA	ATTGACTTCA	GAGTTGGGGA
		TATTTTCATCG	TAAGGGACAA	AAGAACTTTT	TAACTGAAGT	CTCAACCCCT
	1401	TTGCCCATGC	TCCCTAATTC	CCTTCTTTTG	AGTGCTCACA	TAGCCTGCTT
		AACGGGTACG	AGGGATTAAG	GGAAGAAAAC	TCACGAGTGT	ATCGGACGAA
	1451	CCGAATTCTT	GGTATTTTGC	TCTCTGTAAG	GTCATCATTC	AGGTCCAAAG
10		GGCTTAAGAA	CCATAAAACG	AGAGACATTC	CAGTAGTAAG	TCCAGGTTTC
	1501	AAGTCTAGAA	CAGGATGAGG	TCTCAGTGGG	ACCTAGACCA	AGGTTCTTGC
		TTCAGATCTT	GTCC TACTCC	AGAGTCACCC	TGGATCTGGT	TCCAAGAACG
	1551	TCTTCAGAAT	CATCACAGTA	GCCATGGACT	GGA CTCTTCC	ATCTCAGGCA
		AGAAGTCTTA	G TAGTGTCAT	CGGTACCTGA	CCTGAGAAGG	TAGAGTCCGT
15	1601	CTGGCTTTGC	CATCATTTTT	CAGATGTAGC	CTTACCC TGC	CCAGAAAGAC
		GACCGAAACG	G TAGTAAAAA	GTCTACATCG	GAATGGGACG	GGTCTTTCTG
	1651	TCAACACCTC	ACCAGGGGAA	GGGATTTCCCT	ACAACCAAAA	CCCTACTGCA
		AGTTGTGGAG	TGGTCCCCTT	CCCTAAAGGA	TGTTGGTTTT	GGGATGACGT
	1701	GTTTTCACTT	CTTTTTTTTT	TCTTTTTGTT	TATATGGTGG	ATATTTTTTAC
20		CAAAAGTGAA	GAAAAAAAAA	AGAAAAACAA	ATATACCACC	TATAAAAATG
	1751	TTTATATAGT	TTTATTCTTA	TTTTTACTGT	TTTTCATTGT	TTGTTTTTTAA
		AAATATATCA	AAATAAGAAT	AAAAATGACA	AAAAGTAACA	AACAAAAATT
	1801	AAGCTTATCT	TATTATAGCT	TCTTTGTCCC	AGGTTTG CAT	TACTTTCAAT
		TTCGAATAGA	ATAATATCGA	AGAAACAGGG	TCCAAACGTA	ATGAAAGTTA
25	1851	TACAAAAATA	AAGCATGATT	ATTTGAAAAA	AAAAAAAAAA	AAA ACTCGAC
		ATGTTTTTTAT	TTCGTACTAA	TAAACTTTTT	TTTTTTTTTT	TTTTTGAGCTG

SEQ. ID. NO: 3

GAGGTGTTGAGTCTTTCTGGGCA

5

SEQ. ID. NO: 4

ATAGCCTGCTTCCGAATTCTTGG

10 SEQ. ID. NO: 5:

CCCATGCTCCCTAATCCCTTC;

SEQ. ID. NO: 6

GACAGAGCTCGTTTAGTGAACC

15

SEQ. ID. NO. 7

TAGAAGGACACCTAGTCAGAC

20